Get the Stockscreener App
86.53
0.62%
0.53
After Hours:
86.53
Incyte Corp stock is traded at $86.53, with a volume of 5.48M.
It is up +0.62% in the last 24 hours and up +1.25% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$86.00
Open:
$85.86
24h Volume:
5.48M
Relative Volume:
3.07
Market Cap:
$16.90B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
19.67
EPS:
4.4
Net Cash Flow:
$945.58M
1W Performance:
+4.13%
1M Performance:
+1.25%
6M Performance:
+43.40%
1Y Performance:
+29.50%
1-Day Range:
$85.31
$86.81
1-Week Range:
$82.72
$86.81
52-Week Range:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
86.53 | 16.79B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Pallas Capital Advisors LLC Has $2.59 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) EVP Sheila Denton Sells 278 Shares - MarketBeat
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga
Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat
CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - khodrobank.com
Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - khodrobank.com
FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com
US FDA approves Incyte's eczema cream for pediatric patients - Reuters
FDA Approves Incyte's (INCY) Opzelura Cream for Pediatric Dermatitis - GuruFocus
FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus
Incyte gets FDA nod for Opzelura cream in atopic dermatitis treatment - Seeking Alpha
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte stock rating reiterated by Citizens JMP amid promising drug data - Investing.com
Incyte Corporation $INCY Shares Acquired by Sivia Capital Partners LLC - MarketBeat
Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT - Yahoo
INCY Announces New Late-Stage Data on Skin Disease Drug - Yahoo Finance
Retail Trends: Is JZXN in a long term uptrend2025 Earnings Surprises & Low Risk Entry Point Tips - خودرو بانک
Povorcitinib shows promising results for hidradenitis suppurativa By Investing.com - Investing.com Canada
Is Incyte Corporation impacted by rising ratesPortfolio Value Report & Free Verified High Yield Trade Plans - خودرو بانک
INCY: Incyte Unveils Promising Interim Data for Povorcitinib in Phase 3 Trials - GuruFocus
Incyte’s povorcitinib shows strong results in hidradenitis suppurativa trial - Investing.com
Alliancebernstein L.P. Has $14.55 Million Stake in Incyte Corporation $INCY - MarketBeat
Povorcitinib shows promising results for hidradenitis suppurativa - Investing.com
Severe Asthma Market Insights Highlight Expanding Outlook Till - openPR.com
60% Patient Response: Incyte's New Drug Shows Strong Promise in Treating Severe Skin Disease at 24 Weeks - Stock Titan
Incyte Corporation $INCY Stock Position Raised by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Severe Asthma Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca - Barchart.com
OMNI 360 Wealth Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Kera Capital Partners Inc. Invests $339,000 in Incyte Corporation $INCY - MarketBeat
Royal Bank of Canada Sells 14,218 Shares of Incyte Corporation $INCY - MarketBeat
Ashton Thomas Private Wealth LLC Raises Position in Incyte Corporation $INCY - MarketBeat
5,260 Shares in Incyte Corporation $INCY Bought by MBB Public Markets I LLC - MarketBeat
Polycythemia Vera Market: Epidemiology, Treatment Landscape, and Key Players | Incyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfa - Barchart.com
Update Recap: Is Incyte Corporation impacted by rising ratesPrice Action & Daily Volume Surge Signals - khodrobank.com
Woodline Partners LP Grows Holdings in Incyte Corporation $INCY - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $95.86 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
Empowered Funds LLC Buys 115,225 Shares of Incyte Corporation $INCY - MarketBeat
Great Lakes Advisors LLC Grows Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (NASDAQ:INCY) Sees Large Growth in Short Interest - MarketBeat
Incyte Corporation $INCY Shares Sold by Amundi - MarketBeat
Incyte Corporation $INCY Shares Acquired by Acadian Asset Management LLC - MarketBeat
Raymond James Financial Inc. Buys 17,313 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Advances KRAS Cancer Program - Yahoo Finance
Caxton Associates LLP Takes $1.67 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Stock Position Raised by Jacobs Levy Equity Management Inc. - MarketBeat
Incyte Corporation $INCY Shares Acquired by Federation des caisses Desjardins du Quebec - MarketBeat
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress - Business Wire
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):